QL
CPRX

Quarry LP’s Catalyst Pharmaceutical CPRX Stock Holding History

Quarry LP’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99K Sell
95
-9,905
-99% -$292K ﹤0.01% 1375
2026
Q1 		$248K Buy
+10,000
New +$238K 0.04% 293
2025
Q4 		– Sell
-2,011
Closed -$39.6K – 2220
2025
Q3 		$39.6K Buy
+2,011
New +$41.4K 0.01% 974
2025
Q2 		– Sell
-8,000
Closed -$194K – 1786
2025
Q1 		$194K Buy
8,000
+3,000
+60% +$67.6K 0.04% 308
2024
Q4 		$104K Buy
+5,000
New +$107K 0.01% 432
2024
Q3 		– Sell
-16,334
Closed -$253K – 1718
2024
Q2 		$253K Buy
16,334
+10,284
+170% +$160K 0.07% 130
2024
Q1 		$96.4K Buy
6,050
+5,050
+505% +$76.1K 0.02% 250
2023
Q4 		$16.8K Buy
+1,000
New +$13.7K ﹤0.01% 846

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quarry LP's CPRX Position: Q2 2026 in Review

Quarry LP reduced its Catalyst Pharmaceutical (CPRX) stake by 99% in Q2 2026, selling an estimated $292K and leaving 95 shares worth $2.99K. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Quarry LP first reported a position in CPRX in Q4 2023 and has held it in 8 quarters since. The position peaked at $253K in Q2 2024. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Quarry LP held 95 shares of Catalyst Pharmaceutical worth $2.99K as of Q2 2026.
  • Quarry LP sold 9,905 Catalyst Pharmaceutical shares in Q2 2026, an estimated $292K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #1375 holding.
  • Quarry LP first reported a position in Catalyst Pharmaceutical in Q4 2023 and has held it in 8 quarters since.
  • Quarry LP's Catalyst Pharmaceutical position peaked at $253K in Q2 2024.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.